T. Kumagai

发表

In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001.

S. Chaki, S. Okuyama, T. Okubo, 1999, European journal of pharmacology.

The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5‐hydroxytryptamine2A receptor antagonist, in rats

S. Chaki, S. Okuyama, A. Nakazato, 1997, British journal of pharmacology.

In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic.

S. Chaki, T. Funakoshi, R. Yoshikawa, 2002, Life sciences.

In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).

S. Chaki, T. Funakoshi, S. Okuyama, 2002, Life sciences.

In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats

S. Chaki, T. Funakoshi, R. Yoshikawa, 1999, Neuropharmacology.

Synthesis and structure–affinity relationships of 4-(5-Aryl-1,2,3,6-tetrahydropyridino)pyrimidine derivatives as corticotropin-releasing factor1 receptor antagonists

S. Chaki, S. Okuyama, T. Okubo, 2001 .

Chemical modification of aryl-1,2,3,6-tetrahydropyridinopyrimidine derivative to discover corticotropin-releasing factor(1) receptor antagonists: aryl-1,2,3,6-tetrahydropyridino-purine, -3H-1,2,3-triazolo[4,5-d)pyrimidine, -purin-8-one, and -7H-pyrrolo[2,3-d]pyrimidine derivatives.

S. Chaki, S. Okuyama, T. Okubo, 2001, Bioorganic & medicinal chemistry.

Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor1 receptor antagonists.

S. Chaki, S. Okuyama, T. Okubo, 2000, Bioorganic & medicinal chemistry.

Scalable synthesis of (+)-2-amino-3-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid as a potent and selective group II metabotropic glutamate receptor agonist.

A. Nakazato, T. Kumagai, T. Taguchi, 2007, Chemical & pharmaceutical bulletin.

Intramolecular Radical, Knoevenagel, or SN2′ Cyclization of Carbohydrate Derivatives for Access to Enantiomerically Pure 2-Oxospiroalkanes

T. Kumagai, Y. Isshiki, S. Ogawa, 1993 .

Off-Template Claisen Rearrangement of a D-Glucose-Derived Bicyclic Substrate

T. Kumagai, Y. Isshiki, S. Ogawa, 1993 .

Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.

S. Nakanishi, S. Chaki, R. Yoshikawa, 2000, Journal of medicinal chemistry.

Total Syntheses of PI-201 and Related Compounds

T. Kumagai, M. Ishikawa, S. Ogawa, 1996 .

Total Syntheses of PI-201 and Related Compounds.

T. Kumagai, M. Ishikawa, T. Murata, 1997 .

Total synthesis of PI-201, a new platelet aggregation inhibitor : Establishment of its absolute stereochemistry

T. Kumagai, S. Ogawa, T. Murata, 1993 .

Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.

S. Chaki, S. Okuyama, T. Okubo, 1999, The Journal of pharmacology and experimental therapeutics.

A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.

S. Chaki, T. Funakoshi, R. Yoshikawa, 1999, Life sciences.

In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).

S. Chaki, R. Yoshikawa, S. Okuyama, 1997, The Journal of pharmacology and experimental therapeutics.

Derives de 1,2-dihydro-2-oxoquinoline

S. Chaki, T. Okubo, A. Nakazato, 1998 .